Transgenic overexpression and pharmacological administration of FGF21 under obesogenic conditions has been shown to protect animals from diet-induced obesity and improved systemic glucose homeostasis [29,30]. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.